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The continuing 2019-nCoV epidemic threat of novel coronaviruses
to global health — The latest 2019 novel coronavirus outbreak in
Wuhan, China
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
journal homepage: www.elsevier .com/ locate / i j idThe city of Wuhan in China is the focus of global attention due to
an outbreak of a febrile respiratory illness due to a coronavirus
2019-nCoV. In December 2019, there was an outbreak of
pneumonia of unknown cause in Wuhan, Hubei province in China,
with an epidemiological link to the Huanan Seafood Wholesale
Market where there was also sale of live animals. Notification of
the WHO on 31 Dec 2019 by the Chinese Health Authorities has
prompted health authorities in Hong Kong, Macau, and Taiwan to
step up border surveillance, and generated concern and fears that
it could mark the emergence of a novel and serious threat to public
health (WHO, 2020a; Parr, 2020).
The Chinese health authorities have taken prompt public
health measures including intensive surveillance, epidemiolog-
ical investigations, and closure of the market on 1 Jan 2020.
SARS-CoV, MERS-CoV, avian influenza, influenza and
other common respiratory viruses were ruled out. The Chinese
scientists were able to isolate a 2019-nCoV from a patient within
a short time on 7 Jan 2020 and perform genome sequencing of
the 2019-nCoV. The genetic sequence of the 2019-nCoV has
become available to the WHO on 12 Jan 2020 and this has
facilitated the laboratories in different countries to produce
specific diagnostic PCR tests for detecting the novel infection
(WHO, 2020b). The 2019-nCoV is a β CoV of group 2B with at
least 70% similarity in genetic sequence to SARS-CoV and has
been named 2019-nCoV by the WHO.
SARS is a zoonosis caused by SARS-CoV, which first emerged in
China in 2002 before spreading to 29 countries/regions in 2003
through a travel-related global outbreak with 8,098 cases with a
case fatality rate of 9.6%. Nosocomial transmission of SARS-CoV
was common while the primary reservoir was putatively bats,
although unproven as the actual source and the intermediary
source was civet cats in the wet markets in Guangdong (Hui and
Zumla, 2019). MERS is a novel lethal zoonotic disease of humans
endemic to the Middle East, caused by MERS-CoV. Humans are
thought to acquire MERS-CoV infection though contact with
camels or camel products with a case fatality rate close to 35%
while nosocomial transmission is also a hallmark (Azhar et al.,
2019). The recent outbreak of clusters of viral pneumonia due to a
2019-nCoV in the Wuhan market poses significant threats to
international health and may be related to sale of bush meat
derived from wild or captive sources at the seafood market.https://doi.org/10.1016/j.ijid.2020.01.009
1201-9712/© 2020 Published by Elsevier Ltd on behalf of International Society for Infect
creativecommons.org/licenses/by-nc-nd/4.0/).As of 10 Jan 2020, 41 patients have been diagnosed to have
infection by the 2019-nCoV animals. The onset of illness of the 41
cases ranges from 8 December 2019 to 2 January 2020. Symptoms
include fever (>90% cases), malaise, dry cough (80%), shortness of
breath (20%) and respiratory distress (15%). The vital signs were
stable in most of the cases while leucopenia and lymphopenia
were common. Among the 41 cases, six patients have been
discharged, seven patients are in critical care and one died, while
the remaining patients are in stable condition. The fatal case
involved a 61 year-old man with an abdominal tumour
and cirrhosis who was admitted to a hospital due to respiratory
failure and severe pneumonia. The diagnoses included severe
pneumonia, acute respiratory distress syndrome, septic shock
and multi-organ failure. The 2019-nCoV infection in Wuhan
appears clinically milder than SARS or MERS overall in terms of
severity, case fatality rate and transmissibility, which increases
the risk of cases remaining undetected. There is currently no clear
evidence of human to human transmission. At present, 739 close
contacts including 419 healthcare workers are being quarantined
and monitored for any development of symptoms (WHO, 2020b;
Center for Health Protection and HKSAR, 2020). No new cases
have been detected in Wuhan since 3 January 2020. However the
first case outside China was reported on 13th January 2020 in a
Chinese tourist in Thailand with no epidemiological linkage to the
Huanan Seafood Wholesale Market.
The Chinese Health Authorities have carried out very appropriate
and prompt response measures including active case finding, and
retrospective investigations of the current cluster of patients which
have been completed; The Huanan Seafood Wholesale Market has
been temporarily closed to carry out investigation, environmental
sanitation and disinfection; Public risk communication activities
have been carried out to improve public awareness and adoption of
self-protection measures. Technical guidance on novel coronavirus
has been developed and will continue to be updated as additional
information becomes available.
However, many questions about the new coronavirus remain.
While it appears to be transmitted to humans via animals,
the specific animals and other reservoirs need to be identified, the
transmission route, the incubation period and characteristics of the
susceptible population and survival rates. At present, there is
however very limited clinical information of the 2019-nCoVious Diseases. This is an open access article under the CC BY-NC-ND license (http://
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source of the virus, incubation period, epidemic curve, viral
kinetics, transmission route, pathogenesis, autopsy findings and
any treatment response to antivirals among the severe cases. Once
there is any clue to the source of animals being responsible for this
outbreak, global public health authorities should examine the
trading route and source of movement of animals or products
taken from the wild or captive conditions from other parts to
Wuhan and consider appropriate trading restrictions or other
control measures to limit. The rapid identification and contain-
ment of a novel coronavirus virus in a short period of time is a re-
assuring and a commendable achievement by China’s public health
authorities and reflects the increasing global capacity to detect,
identify, define and contain new outbreaks. The latest analysis
show that the Wuhan CoV cluster with the SARS CoV.10 (Novel
coronavirus - China (01): (HU) WHO, phylogenetic tree Archive
Number: 20200112.6885385).
This outbreak brings back memories of the novel coronavirus
outbreak in China, the severe acute respiratory syndrome (SARS) in
China in 2003, caused by a novel SARS-CoV-coronavirus (World
Health Organization, 2019a). SARS-CoV rapidly spread from
southern China in 2003 and infected more than 3000 people,
killing 774 by 2004, and then disappeared – never to be seen again.
However, The Middle East Respiratory Syndrome (MERS) Corona-
virus (MERS-CoV) (World Health Organization, 2019b), a lethal
zoonotic pathogen that was first identified in humans in the Kingdom
of Saudi Arabia (KSA) in 2012 continues to emerge and re-emerge
through intermittent sporadic cases, community clusters and
nosocomial outbreaks. Between 2012 and December 2019, a total of
2465 laboratory-confirmed cases of MERS-CoV infection, including
850deaths(34.4%mortality)werereportedfrom27countriestoWHO,
the majority of which were reported by KSA (2073 cases, 772 deaths.
Whilst several important aspects of MERS-CoV epidemiology,
virology, mode of transmission, pathogenesis, diagnosis, clinical
features, have been defined, there remain many unanswered
questions, including source, transmission and epidemic potential.
The Wuhan outbreak is a stark reminder of the continuing threat of
zoonotic diseases to global health security. More significant and better
targeted investments are required for a more concerted and
collaborative global effort, learning from experiences from all
geographical regions, through a ‘ONE-HUMAN-ENIVRONMENTAL-
ANIMAL-HEALTH’ global consortium to reduce the global threat of
zoonotic diseases(Zumla et al., 2016). Sharingexperience andlearning
from all geographical regions and across disciplines will be key to
sustaining and further developing the progress being made.
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